Evidence map›Paper›PMID 37439014›Full record

ArticleTechnology in cancer research & treatment

Identification of TUBB4A as a Prognostic Biomarker of Melanoma by Transcriptomic Data and

Jiaqi Zhang, Yu Zhang, Jun Liu, Judong Luo, Yifei Yun, Yan Cao

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jiaqi ZhangDepartment of Dermatology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, China.
Yu ZhangDepartment of Radiotherapy, Beijing West Cancer Hospital, Beijing, China.
Jun LiuDepartment of Radiation Oncology, Changzhou Fourth People's Hospital, Changzhou, Jiangsu Province, China.
Judong LuoDepartment of Radiotherapy, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, China.ORCID 0000-0002-3580-9227
Yifei YunDepartment of Radiation Oncology, Changzhou Fourth People's Hospital, Changzhou, Jiangsu Province, China.
Yan CaoDepartment of Dermatology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, China.
Changzhou No.2 People's Hospital · CNSoochow University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Melanoma, ExperimentalSkin NeoplasmsTubulinAnimalsArtemisininsBiomarkersCutaneous Malignant MelanomaHumansNocodazolePrognosisTranscriptomeArtemisininsartenimolBiomarkersNocodazoleTUBB4A protein, humanTubulindifferential expressionmelanomaprognostic biomarkerTUBB4Atubulin

Identifiers

PMID37439014
PMCPMC10345940
OpenAlexW4384120564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.